Pharsight

Daurismo is owned by Pfizer.

Daurismo contains Glasdegib Maleate.

Daurismo has a total of 4 drug patents out of which 0 drug patents have expired.

Daurismo was authorised for market use on 21 November, 2018.

Daurismo is available in tablet;oral dosage forms.

Daurismo can be used as use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Drug patent challenges can be filed against Daurismo from November, 2022.

The generics of Daurismo are possible to be released after 13 April, 2036.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401	PFIZER	Benzimidazole derivatives	Jan, 2031 (7 years from now)
US10414748	PFIZER	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597	PFIZER	Benzimidazole derivatives	Jun, 2028 (5 years from now)
US11168066	PFIZER	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 21, 2023
Orphan Drug Exclusivity (ODE)	Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL